文献速递肿瘤 PET/CT核素与放射性配体治疗

PSMA PET诊断成像在前列腺癌中的当前与新兴临床应用

Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer.
PubMed 文献 · J Nucl Med · 2021-03-12

PSMA在多数前列腺癌细胞高表达,多种PSMA PET显像配体已在全球可用,68Ga-PSMA-11已获FDA和EMA批准,多个国际指南建议在不同临床场景中使用PSMA PET。本综述总结当前或新兴主要适应症的最新文献及推荐判读标准。

要点

  • 初诊前列腺癌中PSMA PET检测盆腔淋巴结和远处转移优于横断面成像并改变临床管理。
  • 复发时PSMA PET检出率高于其他可用成像技术,尤其在低PSA值。
  • PSMA PET可指导寡转移灶定向治疗,并用于去势抵抗性前列腺癌分期和177Lu-PSMA治疗筛选。

核心结论

  • PSMA PET在前列腺癌初诊分期、复发检测、寡转移引导治疗及放射性配体治疗筛选等方面具有重要临床应用价值。

研究设计与样本

  • 本文为叙述性综述,旨在全面概述PSMA PET当前或新兴主要适应症的最新文献及推荐判读标准。

主要发现

  • 初诊前列腺癌中,PSMA PET检测盆腔淋巴结和远处转移优于横断面成像,并带来后续临床管理改变。
  • PSMA PET可能有助于前列腺内肿瘤定位,尤其与多参数MRI联合时。
  • 复发场景中,PSMA PET检出率高于任何其他可用成像技术,尤其在低前列腺特异性抗原值时。
  • PSMA PET持续导致临床管理转变,增加放疗、手术或其他局部治疗比例,减少全身治疗或不治疗。
  • 根治性手术后寡转移性疾病中,初步数据似乎提示治疗PSMA PET阳性病灶后无进展生存获益。

关键数值与推荐

  • 68Ga-PSMA-11已获美国食品药品监督管理局和欧洲药品管理局批准。
  • 多个国际指南建议在不同临床场景中使用PSMA PET检查前列腺癌。
  • PSMA PET可作为分期和把关技术,与去势抵抗性前列腺癌二线治疗联合,并在评估适合177Lu-PSMA等放射性配体治疗的患者时起关键作用。

临床怎么用

  • 在前列腺癌初诊分期、复发检测、寡转移定向治疗决策及放射性配体治疗患者筛选中,可依据指南考虑使用PSMA PET。

局限性

  • 本文为批判性综述,未报告原始研究的具体样本量、阈值、剂量或P值等数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen (PSMA) is highly expressed on most prostate cancer (PCa) cells, and several PSMA ligands for PET imaging are now available worldwide. 68Ga-PSMA-11 has already received U.S. Food and Drug Administration and European Medicines Agency approval, and use of PSMA PET is currently suggested by several international guidelines for investigating PCa in different clinical settings. In primary PCa, PSMA PET has been shown to be superior to cross-sectional imaging for the detection of pelvic lymph nodes and distant metastases with subsequent clinical management changes. Additionally, it might also have a role in intraprostatic tumor localization, especially when combined with multiparametric MRI. In a setting of PCa recurrence, higher detection rates have been observed than for any other available imaging techniques, especially at low prostate-specific antigen values. Furthermore, PSMA PET consistently led to a shift in clinical management, thus increasing the proportion of radiotherapy, surgery, or other focal therapies at the expense of systemic options or no treatment. In oligometastatic disease after radical surgery, PSMA PET may be relevant in guiding a metastasis-directed therapy approach, as preliminary data seem to suggest a benefit in terms of progression-free survival after treatment of PSMA PET-positive lesions. As a staging and gatekeeping technique, PSMA PET represents a reliable whole-body imaging procedure in combination with second-line therapy of castration-resistant PCa, as well as being pivotal when assessing patients eligible for radioligand therapy such as 177Lu-PSMA. This critical review aims at providing a comprehensive overview of the latest literature on the current or emerging main indications, as well as a general outlook on the recommended interpretation criteria for PSMA PET imaging.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Farolfi A, Calderoni L, Mattana F, et al. Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer. J Nucl Med. 2021. PMID: 33712536. doi:10.2967/jnumed.120.257238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。